Tonix Pharmaceuticals Holding Corp.
Start Phase 2 study in acute stress disorder with TNX-102 SL
Delivered after the deadline (51 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 6 Feb 2025
- Due
- 31 Mar 2025
- Delivered
- 21 May 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 2 Study*** Start Expected 1Q'25”
What we found
Evidence strength A What the grades mean
Tonix revised the OASIS Phase 2 start timeline to 1H'25 in March 2025, then announced first patient dosed on May 21, 2025, after the original 1Q'25 deadline.
-
A Tonix Pharmaceuticals SEC filing exhibit (Feb 2025) Original commitment: Phase 2 OASIS study start expected 1Q'25.
-
A Tonix Pharmaceuticals Holding Corp. - Form 8-K - FY2025 SEC 8-K exhibit confirming first patient dosed in OASIS trial on May 21, 2025.
-
B Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study Primary press release confirming actual trial start date.
-
D Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results Revised guidance: study expected to start in first half of 2025, not 1Q.
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Start
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Tonix Pharmaceuticals Holding Corp.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-TNXP-000299 · Corrections policy